-+ 0.00%
-+ 0.00%
-+ 0.00%

Celularity Signs Exclusive Deal With Vesalius to Manufacture Peptide APIs in US

PUBT·10/29/2026 13:00:43
Listen to the news
Celularity Signs Exclusive Deal With Vesalius to Manufacture Peptide APIs in US
  • Celularity entered an exclusive manufacturing agreement with Vesalius Longevity Labs to establish a U.S. supply platform for Peptual-branded peptide active pharmaceutical ingredients.
  • Manufacturing at its Florham Park, New Jersey, facility will use supplier-provided bulk peptides for downstream processing and testing.
  • Supply to licensed U.S. compounding pharmacies is contingent on FDA listing of covered peptides as eligible bulk drug substances.
  • The collaboration excludes GLP-1 receptor agonists and other weight-loss peptides.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Celularity Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20261029804397) on October 29, 2026, and is solely responsible for the information contained therein.